A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery
Public ClinicalTrials.gov record NCT02542384. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of Intravenous CR845 in Patients Undergoing Abdominal Surgery
Study identification
- NCT ID
- NCT02542384
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Enrollment
- 451 participants
Conditions and interventions
Conditions
Interventions
- CR845 IV 1 mcg/kg Drug
- CR845 IV 0.5 mcg/kg Drug
- Placebo IV Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2015
- Primary completion
- Mar 31, 2018
- Completion
- May 31, 2018
- Last update posted
- May 30, 2019
2015 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cara Therapeutics Study Site | Sheffield | Alabama | — | — |
| Cara Therapeutics Study Site | New Haven | Connecticut | — | — |
| Cara Therapeutics Study Site | Bradenton | Florida | 34209 | — |
| Cara Therapeutics Study Site | Gainesville | Florida | — | — |
| Cara Therapeutics Study Site | Maitland | Florida | — | — |
| Cara Therapeutics Study Site | Miami Gardens | Florida | — | — |
| Cara Therapeutics Study Site | Pensacola | Florida | 32503 | — |
| Cara Therapeutics Study Site | St. Petersburg | Florida | 33713 | — |
| Cara Therapeutics Study Site | Chicago | Illinois | — | — |
| Cara Therapeutics Study Site | Boston | Massachusetts | — | — |
| Cara Therapeutics Study Site | Camden | New Jersey | 08103 | — |
| Cara Therapeutics Study Site | Neptune City | New Jersey | — | — |
| Cara Therapeutics Study Site | Durham | North Carolina | 27710 | — |
| Cara Therapeutics Study Site | Cleveland | Ohio | — | — |
| Cara Therapeutics Study Site | Columbus | Ohio | — | — |
| Cara Therapeutics Study Site | Pittsburgh | Pennsylvania | — | — |
| Cara Therapeutics Study Site | Chattanooga | Tennessee | — | — |
| Cara Therapeutics Study Site | Bellaire | Texas | — | — |
| Cara Therapeutics Study Site | Fort Worth | Texas | — | — |
| Cara Therapeutics Study Site | Houston | Texas | — | — |
| Cara Therapeutics Study Site | Plano | Texas | — | — |
| Cara Therapeutics Study Site | San Antonio | Texas | — | — |
| Cara Therapeutics Study Site | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02542384, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02542384 live on ClinicalTrials.gov.